Study shows benefit of treatment to improve blood glucose levels in young people with type 2 diabetes
Latest study reports blood glucose levels can be significantly reduced by treatment with Forxiga (dapagliflozin).
Diagnosis of type 2 diabetes in children and adolescents is increasing rapidly according to latest global figures.
In 2021, it was estimated that there were approximately 41,600 new cases of type 2 diabetes diagnosed worldwide.
However, despite the rise in new cases of the condition for young people there are still limited treatments options available. Until more recently a type 2 diabetes diagnosis would not be anticipated until later in life, with development of the condition often linked to lifestyle factors including diet and exercise.
The T2NOW study reported a significant reduction of average blood glucose levels for patients treated with Forxiga (dapagliflozin) compared with patients receiving a placebo treatment.
The results of the global study were recently published in The New England Journal of Medicine Evidence and presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) Congress.
UK participation of the study was organised by the National Institute for Health and Care Research (NIHR) Wellcome Clinical Research Facility at Birmingham.
Researchers concluded that dapagliflozin can provide clinically meaningful improvements in glycemia for children and adolescents with type 2 diabetes (T2D).1 The safety results in this patient population were consistent with those in adults with T2D, in line with the well-established safety profile for Forxiga.1
Naim Shehadeh, Professor of Endocrinology, Rambam Health Care Campus, Israel, said: “The significant decrease in blood glucose levels that we observed in patients receiving Forxiga may indicate a reduction in the progression of type 2 diabetes and its complications. This is an important treatment consideration as children and adolescents with type 2 diabetes often experience earlier onset of complications and faster advancement of disease compared to adults with the same condition.”
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “Today’s results from one of the largest studies into children suffering from type 2 diabetes, offers hope. Despite the growing global burden of type 2 diabetes among children and adolescents, the treatment options available are currently limited. It is well documented that some patients find injectable therapies challenging, making the need for effective oral treatment alternatives paramount.”
Read the report in The New England Journal of Medicine Evidence
I would like to make a regular donation of
I would like to make a single donation of